Literature DB >> 7838376

Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A.

C X Gong1, I Grundke-Iqbal, K Iqbal.   

Abstract

Microtubule-associated protein tau is abnormally hyperphosphorylated in the brain of patients with Alzheimer's disease, and is the major protein subunit of paired helical filaments. There is also a significant pool of non-paired helical filament abnormally phosphorylated tau in Alzheimer's disease brain. In the present study, the site-specific dephosphorylation of this Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A was studied and compared with that by protein phosphatase-2B. The dephosphorylation was detected by its interaction with several phosphorylation-dependent antibodies to various abnormal phosphorylation sites. Protein phosphatase-2A was able to dephosphorylate the abnormally phosphorylated tau at Ser-46, Ser-199, Ser-202, Ser-396 and Ser-404, but not at Ser-235 (the amino acids are numbered according to the largest isoform of human tau, tau441). Two major types of protein phosphatase-2A, protein phosphatase-2A1 and -2A2, dephosphorylated the abnormally phosphorylated tau at approximately the same rate. After the abnormally phosphorylated tau was dephosphorylated by protein phosphatase-2A, its relative mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis increased. The dephosphorylation of the abnormal tau by protein phosphatase-2A1 and -2A2 was markedly stimulated by Mn2+. These results suggest that tau dephosphorylation is catalysed by protein phosphatase-2A in addition to protein phosphatase-2B. A deficiency of either protein phosphatase-2A or -2B, or both, may be involved in abnormal phosphorylation of tau in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7838376     DOI: 10.1016/0306-4522(94)90400-6

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  51 in total

1.  Multiple forms of phosphatase from human brain: isolation and partial characterization of affi-gel blue binding phosphatases.

Authors:  L Y Cheng; J Z Wang; C X Gong; J J Pei; T Zaidi; I Grundke-Iqbal; K Iqbal
Journal:  Neurochem Res       Date:  2000-01       Impact factor: 3.996

Review 2.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

3.  Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects.

Authors:  Fabio Di Domenico; Rukhsana Sultana; Eugenio Barone; Marzia Perluigi; Chiara Cini; Cesare Mancuso; Jian Cai; William M Pierce; D Allan Butterfield
Journal:  J Proteomics       Date:  2011-04-13       Impact factor: 4.044

Review 4.  Tau pathology generated by overexpression of tau.

Authors:  I Grundke-Iqbal; K Iqbal
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 5.  Tau in neurodegenerative diseases: tau phosphorylation and assembly.

Authors:  J Avila; M Pérez; F Lim; A Gómez-Ramos; F Hernández; J J Lucas
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 6.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

Review 7.  Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration.

Authors:  M L Billingsley; R L Kincaid
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

8.  Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  J Neuropathol Exp Neurol       Date:  2008-05       Impact factor: 3.685

9.  PP2A methylation controls sensitivity and resistance to β-amyloid-induced cognitive and electrophysiological impairments.

Authors:  Russell E Nicholls; Jean-Marie Sontag; Hong Zhang; Agnieszka Staniszewski; Shijun Yan; Carla Y Kim; Michael Yim; Caitlin M Woodruff; Erland Arning; Brandi Wasek; Deqi Yin; Teodoro Bottiglieri; Estelle Sontag; Eric R Kandel; Ottavio Arancio
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-07       Impact factor: 11.205

10.  Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease.

Authors:  Jin-Jing Pei; Cheng-Xin Gong; Wen-Lin An; Bengt Winblad; Richard F Cowburn; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.